Literature DB >> 31056305

Ectopic pregnancy and outcomes of future intrauterine pregnancy.

Mélanie Chouinard1, Marie-Hélène Mayrand2, Aimina Ayoub3, Jessica Healy-Profitós3, Nathalie Auger4.   

Abstract

OBJECTIVE: To provide information on the birth outcomes of future intrauterine pregnancies in women whose first pregnancy was ectopic.
DESIGN: Population-based longitudinal cohort study.
SETTING: All hospitals in Quebec, Canada, 1989-2013. PATIENT(S): Group surgically treated for an ectopic first pregnancy: 15,823 women; comparison group with an intrauterine first pregnancy: 1,101,748 women. INTERVENTION(S): Not applicable. MAIN OUTCOME MEASURE(S): Repeat ectopic pregnancy, future delivery of a live infant, stillbirth, cesarean delivery, preterm birth, low birth weight, preeclampsia, gestational diabetes, and postpartum hemorrhage as well as other outcomes of pregnancy. RESULT(S): The overall prevalence of ectopic first pregnancy was 14.2 per 1,000 women, of whom 10% of women with an ectopic first pregnancy had a future ectopic. Regardless of age, women with ectopic first pregnancies had an increased risk of adverse birth outcomes at future intrauterine pregnancies, including 1.27 times the risk of preterm birth (95% confidence interval [CI], 1.18-1.37), 1.20 times the risk of low birth weight (95% CI, 1.10-1.31), 1.21 times the risk of placental abruption (95% CI, 1.04-1.41), and 1.45 times the risk of placenta previa (95% CI, 1.10-1.91). Older women with a prior ectopic pregnancy had particularly elevated risks of placental abruption (risk ratio 1.42; 95% CI, 1.16-1.69). CONCLUSION(S): Women with ectopic first pregnancies have an increased risk of adverse birth outcomes during subsequent intrauterine pregnancies. These women may benefit from closer clinical management in pregnancy to prevent adverse birth outcomes.
Copyright © 2019 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cohort study; ectopic; fertility; pregnancy; pregnancy outcome

Mesh:

Year:  2019        PMID: 31056305     DOI: 10.1016/j.fertnstert.2019.03.019

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  [Talin1 is highly expressed in the fallopian tube and chorionic villi to promote trophoblast invasion in tubal pregnancy].

Authors:  P Qiu; X Lin; G Deng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-04-20

2.  Time to pregnancy in women with previous ectopic pregnancy undergoing in vitro fertilization treatment: a retrospective cohort study.

Authors:  Yamei Xue; Fuxing Zhang; Haocheng Zhang; Songying Zhang
Journal:  Sci Rep       Date:  2022-05-25       Impact factor: 4.996

Review 3.  Roles of steroid hormones in oviductal function

Authors:  Brooke Barton; Gerardo Herrera; Prashanth Anamthathmakula; Jenna Rock; Anna Willie; Emily Harris; Ken-Ichi Takemaru; Wipawee Winuthayanon
Journal:  Reproduction       Date:  2020-03-01       Impact factor: 3.906

4.  Setting priorities in the conventional approaches in managing ectopic pregnancy; is it time to reform? A teaching hospital experience.

Authors:  Kamil M Fram; Shawqi Saleh; Fidaa Thikerallah; Farah Fram; Rand Fram; Hadeel Rawahneh; Mai Khrais; Tamara Darwish
Journal:  Prz Menopauzalny       Date:  2020-01-15

5.  Pristimerin Suppresses Trophoblast Cell Epithelial-Mesenchymal Transition via miR-542-5p/EGFR Axis.

Authors:  Chang Shu; Xiaowei Yu; Shihuan Cheng; Jili Jing; Cong Hu; Bo Pang
Journal:  Drug Des Devel Ther       Date:  2020-11-02       Impact factor: 4.162

6.  Pregnancy outcomes following in vitro fertilization treatment in women with previous recurrent ectopic pregnancy.

Authors:  Yamei Xue; Xiaomei Tong; Haocheng Zhang; Songying Zhang
Journal:  PLoS One       Date:  2022-08-15       Impact factor: 3.752

7.  Risk factors and clinical characteristics of recurrent ectopic pregnancy: A case-control study.

Authors:  Xinyan Wang; Lu Huang; Yan Yu; Sheng Xu; Yucheng Lai; Wenjie Zeng
Journal:  J Obstet Gynaecol Res       Date:  2020-04-12       Impact factor: 1.730

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.